常茂生物2026年中期营收2.90亿元,经营利润600.80万元

公告速递
Sep 01

本季度信息

截至2026年6月30日止六个月,常茂生物实现营收合计2.90亿元,较上年同期的2.72亿元增长约6.3%。同期经营利润由上年同期的-1,948.50万元转为正向的600.80万元。毛利为4,254.10万元,较上年同期的1,315.10万元同比增长约223%。毛利率从上年同期的4.8%提升至14.7%,经营现金流净额约4,299.60万元,同比增幅约180%。

在成本结构方面,销售费用约454.40万元,同比小幅增加;管理费用约3,327.90万元,同比增幅约4%。

业务分项

分地区来看,中国内地市场收入为2.37亿元,同比保持增长;西班牙市场收入为0.10亿元;丹麦及其他地区收入分别为0.60亿元和0.37亿元,各自有所波动。公司重点关注高毛利产品及主要客户需求,积极调整产品结构并稳步推进产研结合,整体业务表现持续改善。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10